This article is more than 5 years old. Information may no longer be current.
Topical colistin 0.19% a potential alternative treatment for P. aeruginosa keratitis
Click Here to Manage Email Alerts
The early use of topical colistin 0.19% eye drops may be an effective alternative for managing multi-drug-resistant Pseudomonas aeruginosa bacterial keratitis, according to study findings.
Researchers retrospectively reviewed medical records to collect clinical and microbiological data from eight patients with P. aeruginosa bacterial keratitis who were treated with colistin 0.19% eye drops.
All patients had undergone corneal scrapings and received half-hourly medical therapy and treatment with broad-spectrum antibiotics; treatment was changed over to topical colistin 0.19% once sensitivity reports were available, according to the researchers.
Treatment was considered to be a complete success if the infection resolved with scar formation without subsequent recurrence for up to 2 weeks, whereas partial success was considered if the infection also required cyanacrylate glue application before resolution of the infection.
Among the 1,923 total culture-positive ocular infections managed during the period studied, 743 were bacterial, and 141 were caused by P. aeruginosa.
Colistin therapy was successful in seven of eight patients, with the infiltrate decreasing with resolution of infection in a mean time of 30.5 days. Mean infiltrate size was 15.41 mm2 and was full-size in five patients, according to the researchers.
The researchers noted that complete success occurred in four patients, and three patients had partial success. Additionally, there were no reported complications to the topical colistin therapy.
Disclosure: The authors have no relevant financial disclosures.
Click Here to Manage Email Alerts